PirA or PirB binding nanobodies protect whiteleg shrimp from acute hepatopancreatic necrosis disease and replace antibiotics

NovoBind develops next-generation biologics using nanobodies that attack disease

By 2050, around 2 million people — the majority aged over 70 — could die from drug-resistant infections each year.